179 related articles for article (PubMed ID: 35920658)
41. Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.
Hunter Z; Tumban E; Dziduszko A; Chackerian B
Vaccine; 2011 Jun; 29(28):4584-92. PubMed ID: 21549786
[TBL] [Abstract][Full Text] [Related]
42. A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
Gambhira R; Karanam B; Jagu S; Roberts JN; Buck CB; Bossis I; Alphs H; Culp T; Christensen ND; Roden RB
J Virol; 2007 Dec; 81(24):13927-31. PubMed ID: 17928339
[TBL] [Abstract][Full Text] [Related]
43. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
44. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge.
Pal S; Theodor I; Peterson EM; de la Maza LM
Vaccine; 1997 Apr; 15(5):575-82. PubMed ID: 9160528
[TBL] [Abstract][Full Text] [Related]
45. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.
Safrit JT; Fung MS; Andrews CA; Braun DG; Sun WN; Chang TW; Koup RA
AIDS; 1993 Jan; 7(1):15-21. PubMed ID: 7680205
[TBL] [Abstract][Full Text] [Related]
46. Humoral immunity and protection of mice challenged with homotypic or heterotypic parvovirus.
Hansen GM; Paturzo FX; Smith AL
Lab Anim Sci; 1999 Aug; 49(4):380-4. PubMed ID: 10480642
[TBL] [Abstract][Full Text] [Related]
47. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
[TBL] [Abstract][Full Text] [Related]
48. Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2.
Corbeil S; Seguin C; Trudel M
Vaccine; 1996 Apr; 14(6):521-5. PubMed ID: 8782350
[TBL] [Abstract][Full Text] [Related]
49. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
[TBL] [Abstract][Full Text] [Related]
50. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
Roberts PL; Duncan BE; Raybould TJ; Watson DH
J Gen Virol; 1985 May; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
[TBL] [Abstract][Full Text] [Related]
51. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
Gauduin MC; Parren PW; Weir R; Barbas CF; Burton DR; Koup RA
Nat Med; 1997 Dec; 3(12):1389-93. PubMed ID: 9396610
[TBL] [Abstract][Full Text] [Related]
52. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection.
Lim XF; Jia Q; Khong WX; Yan B; Premanand B; Alonso S; Chow VT; Kwang J
PLoS One; 2012; 7(1):e29751. PubMed ID: 22279543
[TBL] [Abstract][Full Text] [Related]
53. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
[TBL] [Abstract][Full Text] [Related]
54. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
[TBL] [Abstract][Full Text] [Related]
55. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
56. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
[TBL] [Abstract][Full Text] [Related]
57. Protection from retinal necrosis by passive transfer of monoclonal antibody specific for herpes simplex virus glycoprotein D.
Atherton SS
Curr Eye Res; 1992 Jan; 11(1):45-52. PubMed ID: 1313751
[TBL] [Abstract][Full Text] [Related]
58. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
Parren PW; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR
J Virol; 2001 Sep; 75(17):8340-7. PubMed ID: 11483779
[TBL] [Abstract][Full Text] [Related]
59. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
Chan WL; Lukig ML; Liew FY
J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536
[TBL] [Abstract][Full Text] [Related]
60. Role of antibody response in recovery from K-papovavirus infection in mice.
Mokhtarian F; Shah KV
Infect Immun; 1980 Sep; 29(3):1169-79. PubMed ID: 6968719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
